Insulet Corporation PODD
At closeNov 12, 2026, 4:36 PM EST
After hours · Nov 12, 4:36 PM ET
- YTD
- -47.48%
- 1 year
- -55.68%
- Market cap
- 10.36B
- Revenue (ttm)
- 3.19B
- Profit margin
- 13.44%
- EPS (ttm)
- 6.12
- Shares out
- 69.37M
- P/E ratio
- 24.39
- Forward P/E
- 18.87
- YTD return
- -47.48%
- 1-year return
- -55.68%
- Volume
- 745.76K
- Avg volume
- 1.58M
- Open
- 150.42
- Previous close
- 150.03
- Day's range
- 148.80 – 151.60
- 52-week range
- 126.40 – 354.88
- Beta
- 1.05
- Analysts
- Buy
- Price target
- 178.57 (+19.6%)
- Earnings date
- Feb 17, 2027
5D -4.79 (-3.11%)
Key statistics
- Enterprise value
- 10.86B
- PEG ratio
- 1.17
- Price / sales
- 3.25
- Price / book
- 6.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 19.20%
- Free cash flow
- 113.51M
- Total cash
- 584.40M
- Total debt
- 1.04B
- Return on equity
- 28.93%
- Short % of float
- 8.67%
- 50-day average
- 142.08
- 200-day average
- 173.76
Analyst view
Consensus: buy
- Target (low)
- 160.00
- Target (mean)
- 178.57
- Target (high)
- 200.00
- Strong buy4
- Buy11
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 1.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 1.74 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.59 | 1.99 | +0.40 | +25.16% |
| Aug 5, 2026 | Jun 30, 2026 | 1.47 | 1.66 | +0.19 | +12.93% |
| May 6, 2026 | Mar 31, 2026 | 1.19 | 1.42 | +0.23 | +19.33% |
| Feb 18, 2026 | Dec 31, 2025 | 1.47 | 1.55 | +0.08 | +5.44% |
| Nov 6, 2025 | Sep 30, 2025 | 1.14 | 1.24 | +0.10 | +8.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Truist Securities | reit | Hold | Hold |
| Nov 6, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 5, 2026 | UBS | main | Neutral | Neutral |
| Nov 5, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 5, 2026 | Citigroup | main | Neutral | Neutral |
| Nov 5, 2026 | Leerink Partners | main | Market Perform | Market Perform |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- insulet.com
News
Why Insulet (PODD) is a Top Growth Stock for the Long-Term 
Insulet (PODD) Just Overtook the 20-Day Moving Average 
Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes" 
Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160 
For World Diabetes Day, Insulet Launches “Give Yourself the Freedom to” Campaign, Encouraging People with Diabetes to Prioritize Their Well-Being 
Insulet Corporation $PODD Shares Purchased by Chicago Partners Investment Group LLC 
Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165 
UBS Maintains Neutral on Insulet, Raises Price Target to $171 - JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170
- Citigroup Maintains Neutral on Insulet, Raises Price Target to $170
Your note
Sign in to keep a note on PODD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENJAMIN ERIC | Chief Operating Officer | Stock Award(Grant) | Feb 23, 2026 | 24,512 |
| CHADWICK ANA MARIA | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2025 | 16,028 |
| FIELD MARK N | Chief Technology Officer | Stock Award(Grant) | Feb 24, 2025 | 13,915 |
| HOLLINGSHEAD JAMES R | Chief Executive Officer | Stock Award(Grant) | Feb 24, 2025 | 68,068 |
| HOPFIELD JESSICA | Director | Stock Award(Grant) | May 19, 2026 | 29,355 |
| KAPPLES JOHN W. | General Counsel | Stock Award(Grant) | Feb 23, 2026 | 28,119 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.64% | 6,690,192 | 998.78M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 4,525,333 | 675.59M | Jun 29, 2026 |
| State Street Corporation | 4.61% | 3,197,555 | 477.36M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.43% | 3,075,932 | 459.21M | Jun 29, 2026 |
| AQR Capital Management, LLC | 3.54% | 2,455,135 | 366.53M | Jun 29, 2026 |
| Two Sigma Investments, LP | 2.74% | 1,903,734 | 284.21M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,199,429 | 328.35M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.58% | 1,792,909 | 267.66M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,589,038 | 237.23M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 2.04% | 1,418,299 | 211.74M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 925,214 | 138.13M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 916,226 | 136.78M | Jun 29, 2026 |